A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain

Rascol, Olivier; Zesiewicz, Theresa; Chaudhuri, K. Ray; Asgharnejad, Mahnaz; Surmann, Erwin; Dohin, Elisabeth; Nilius, Sigrid M.; Bauer, Lars

doi:10.1002/jcph.678

Cited by 91 publications

(65 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As presented in Figure S1, 110 publications involving 24,864 participants were finally included in the present study after screening 1,154 publications according to the inclusion criteria1315161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111…”

Section: Resultsmentioning

confidence: 99%

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Zhuo

Zhu

Jiang³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a long term disorder affects the central nervous system and we aim to determine the relative efficacy of the current available drugs used in PD. Firstly, we performed a systematic review in current literature and eligible studies were retrieved from online databases, relevant data were extracted. Efficacy of these medications was assessed by different Unified Parkinson’s Disease Rating Scales (UPDRS). Mean difference (MD) and odds ratio (OR) were produced by pairwise or network meta-analysis (NMA). Finally, we performed a cluster analysis for the included medications with respect to their surface under the cumulative ranking curve (SUCRA). Pairwise meta-analysis suggests that selegiline had a higher ranking in UPDRS II, UPDRS III and UPDRS total than bromocriptine and levodopa. Selegiline was more tolerable than bromocriptine (OR = 0.62, CI: 0.39 to 0.98) and pramipexole was less tolerable than levodopa (OR = 1.43, CI = 1.00 to 2.04). Results of NMA indicate that patients with levodopa, pramipexole, ropinirole and selegiline exhibited a significantly improved UPDRS III than those with lazabemide. To sum up, levodopa, selegiline, ropinirole and rotigotine were recommended for PD patients as they appeared relatively high efficacy and tolerability.

show abstract

Section: Resultsmentioning

confidence: 99%

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Zhuo

Zhu

Jiang³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…In addition, PD duration appeared as an independent influencing factor in both models highlighting the prominence of the disease progression over time on the patients’ HRQoL. Interestingly, two studies have now reported the efficacy of dopaminergic (rotigotine patch) 27 and non-dopaminergic (oxycodone with naloxone) 12 agents on pain in randomised placebo-controlled studies. Using the KPPS, the dominant pains responding to the active agents were fluctuation related pain (rotigotine) and musculoskeletal pain (oxycodone with naloxone) and thus a tangible effect of these therapies on HRQoL could be envisaged.…”

Section: Discussionmentioning

confidence: 99%

“…Using the KPPS, the dominant pains responding to the active agents were fluctuation related pain (rotigotine) and musculoskeletal pain (oxycodone with naloxone) and thus a tangible effect of these therapies on HRQoL could be envisaged. 12, 27 …”

Section: Discussionmentioning

confidence: 99%

Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale

Martinez‐Martín

Rojo-Abuín

Rizos

et al. 2017

npj Parkinson's Disease

View full text Add to dashboard Cite

In Parkinson’s disease, pain is a prevalent and complex symptom of diverse origin. King’s Parkinson’s disease pain scale, assesses different pain syndromes, thus allowing exploration of its differential prevalence and influence on the health-related quality of life of patients. Post hoc study 178 patients and 83 matched controls participating in the King’s Parkinson’s disease pain scale validation study were used. For determining the respective distribution, King’s Parkinson’s disease pain scale items and domains scores = 0 meant absence and ≥1 presence of the symptom. The regular scores were used for the other analyses. Health-related quality of lifewas evaluated with EQ-5D-3L and PDQ-8 questionnaires. Parkinson’s disease patients experienced more pain modalities than controls. In patients, Pain around joints (King’s Parkinson’s disease pain scale item 1) and Pain while turning in bed (item 8) were the most prevalent types of pain, whereas Burning mouth syndrome (item 11) and Pain due to grinding teeth (item 10) showed the lowest frequency. The total number of experienced pain modalities closely correlated with the PDQ-8 index, but not with other variables. For all pain types except Pain around joints (item 1) and pain related to Periodic leg movements/RLS (item 7), patients with pain had significantly worse health-related quality of life. The influence of pain, as a whole, on the health-related quality of life was not remarkable after adjustment by other variables. When the particular types of pain were considered, adjusted by sex, age, and Parkinson’s disease duration, pain determinants were different for EQ-5D-3L and PDQ-8. King’s Parkinson’s disease pain scale allows exploring the distribution of the diverse syndromic pain occurring in Parkinson’s disease and its association with health-related quality of life.

show abstract

“…Pain severity was reported in 8 trials using the pain subscale of the Visual Analogue Scale (VAS-P) [17,24,26,27,29,30,33,35], in 8 using section 39 of the Parkinson's Disease Questionnaire-39 [16,22,23,31,32,36,37,39], in 4 using the Likert pain scale [18,19,34,38], in 1 using the King Parkinson's Disease Pain Scale [21], in 1 using question 1.9 of the Movement Disorders Society -Unified Parkinson's Disease Rating Scale (MDS-UPDRS Q1.9) [25], in 1 using the McGill Pain Scale [20], and in 1 trial using the Daily Pain Rating Sheet [28] (Table 1).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…The number of trials for each identifiable therapeutic intervention category was 3 for dopaminergic agonists [17][18][19], 2 for cannabinoids and opioids [20,21], 3 for surgical methods [22][23][24], 4 for electrical or Chinese therapies [25][26][27][28], 2 for pardoprunox [29,30], 2 for safinamide [16], 1 for catechol-O-methyltransferase (COMT) inhibitors [31], 1 for multidisciplinary team care [32], and 7 for miscellaneous therapies. Miscellaneous therapies included hydrotherapy [33,34], massage therapy [35], gym training [36], mindfulness therapy [37], vibration therapy [38], and power yoga [39] (Table 1, with further intervention details in Appendix 4).…”

Section: Study Characteristicsmentioning

confidence: 99%

Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Pain in Parkinson’s disease (PD) is a debilitating symptom with a prevalence of 68%, yet is untreated 50% of the time. What is unclear, however, is which treatment is optimal for minimizing pain severity in PD. Thus, the objective of this systematic review and meta-analysis was to investigate the efficacy of a variety of novel, complimentary, and conventional treatments for pain in PD and elucidate which therapy is the most effective. A systematic search was performed using MEDLINE, PsycINFO, Embase, CINAHL, and CENTRAL databases. To identify additional articles, manual searches of reference lists of included trials were also searched. Major neurology conference proceedings occurring between January 2014 and February 2018 were also searched to identify unpublished studies that may be potentially eligible. Twenty-five randomized controlled trials that encompassed medical, surgical, and complementary therapies met our inclusion criteria and exhibited moderate quality evidence. Two reviewers conducted assessments for study eligibility, risk of bias, data extraction, and quality of evidence rating. A conservative random-effects model was used to pool effect estimates of pain severity. The greatest reductions in pain were found with safinamide (Standardized mean difference = –4.83, 95% CI [–5.07 to –4.59], p < 0.0001), followed by cannabinoids and opioids, multidisciplinary team care, catechol-O-methyltransferase inhibitors, and electrical and Chinese therapies. Moderate effects in reducing pain were in pardoprunox and surgery, while the weakest effects were in dopaminergic agonists and miscellaneous therapies. Safinamide is an important adjunct to standard parkinsonian medication for alleviating pain in PD.

show abstract

A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain

Cited by 91 publications

References 46 publications

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Comparison for Efficacy and Tolerability among Ten Drugs for Treatment of Parkinson’s Disease: A Network Meta-Analysis

Distribution and impact on quality of life of the pain modalities assessed by the King’s Parkinson’s disease pain scale

Comprehensive Examination of Therapies for Pain in Parkinson’s Disease: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About